10.25402/FSOA.10110842.v1 Chaitanya Kumar Thota Chaitanya Kumar Thota Jasmine Bagga Jasmine Bagga Srikanth Chiliveru Srikanth Chiliveru Sakshi Kohli Sakshi Kohli Asmi Bharadwaj Asmi Bharadwaj Minish Jain Minish Jain Shriram Inamdar Shriram Inamdar Bandana Sharan Bandana Sharan Supplementary Figure 1. Substantial remission of Prostate Adenocarcinoma with Dendritic Cell therapy APCEDEN® in combination with chemotherapy Future Science Group 2019 Prostate adenocarcinoma Immunotherapy APCEDEN® Dendritic cells interferon gamma IFNγ Neutrophil lymphocyte ratio NLR Platelet lymphocyte ratio PLR Treg Regulatory T Cells Nephrology and Urology Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies) Cancer Therapy (excl. Chemotherapy and Radiation Therapy) 2019-10-31 16:14:11 Figure https://future-science-group.figshare.com/articles/figure/Supplementary_Figure_1_Substantial_remission_of_Prostate_Adenocarcinoma_with_Dendritic_Cell_therapy_APCEDEN_in_combination_with_chemotherapy/10110842 <div>Supplementary Figure 1. Substantial remission of Prostate Adenocarcinoma with Dendritic Cell therapy APCEDEN® in combination with chemotherapy</div><div><br></div><div>Phenotypic assessment of dendritic cells before packaging of six doses of APCEDEN® treatment.</div><div><br></div>